Surveillance of gastric intestinal metaplasia for the prevention of gastric cancer

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 9, 2013, Pages

  O'Connor, Anthony ^a   Mcnamara, Deirdre ^a   O'Moráin, Colm A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PEPSINOGEN I; PEPSINOGEN II;

ALL CAUSE MORTALITY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER PREVENTION; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; ESOPHAGOGASTRODUODENOSCOPY; GASTROINTESTINAL ENDOSCOPY; HUMAN; INTESTINE METAPLASIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; STOMACH BIOPSY; STOMACH CANCER; SYSTEMATIC REVIEW; ADENOCARCINOMA; METAPLASIA; PATHOLOGY; PRECANCEROUS CONDITIONS; STOMACH; STOMACH NEOPLASMS; PRECANCER; STOMACH TUMOR;

ADENOCARCINOMA; HUMANS; METAPLASIA; PRECANCEROUS CONDITIONS; STOMACH; STOMACH NEOPLASMS;

EID: 84898643868     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009322.pub2     Document Type: Review

References (43)

1. Goldstein NS. Gastric cardia intestinal metaplasia: biopsy follow-up of 85 patients. Modern Pathology 2000;13(10):1072-9.
2. Rokkas T, Filipe MI, Sladen GE. Detection of an increased incidence of early gastric cancer in patients with intestinal metaplasia type III who are closely followed up. Gut 1991;32(10):1110-3.
3. Whiting JL, Sigurdsson A, Rowlands DC, Hallissey MT, Fielding JWL. The long term results of endoscopic surveillance of premalignant gastric lesions. Gut 2002;50:378-81.
4. Asaka M, Kato M, Takahashi S, Fukuda Y, Sugiyama T, Ota H, et al.Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition. Helicobacter 2010;15(1):1-20.
5. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50(4):1088-101. [PUBMED: 7786990]
6. Capelle LG, Haringsma J, de Vries AC, Steyerberg EW, Biermann K, van Dekken H, et al.Narrow band imaging for the detection of gastric intestinal metaplasia and dysplasia during surveillance endoscopy. Digestive Diseases and Sciences 2010;55(12):3442-8.
7. Cassaro M, Rugge M, Gutierrez O, Leandro G, Graham DY, Genta RM. Topographic patterns of intestinal metaplasia and gastric cancer. American Journal of Gastroenterology 2000;95(6):1431-8.
8. Cooper SC, El-agib A, Dar S, Mohammed I, Nightingale P, Murray IA, et al.Endoscopic surveillance for Barrett's oesophagus: the patients' perspective. European Journal of Gastroenterology and Hepatology 2009;21(8):850-4.
9. Correa P, Haenszel W, Cuello C, Tannenbaum S, Archer M. A model for gastric cancer epidemiology. Lancet 1975;2(7924):58-60.
10. Correa P, Piazuelo MB, Wilson KT. Pathology of gastric intestinal metaplasia: clinical implications. American Journal of Gastroenterology 2010;105(3):493-8.
11. de Vries AC, van Grieken NC, Looman CW, Casparie MK, de Vries E, Meijer GA, et al.Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134(4):945-52.
12. Dinis-Ribeiro M, da Costa-Pereira A, Lopes C, Moreira-Dias L. Feasibility and cost-effectiveness of using magnification chromoendoscopy and pepsinogen serum levels for the follow-up of patients with atrophic chronic gastritis and intestinal metaplasia. Journal of Gastroenterology and Hepatology 2007;22(10):1594-604.
13. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al.Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva. Endoscopy 2012;44(1):74-94.
14. Edge SB, Byrd DR, Compoton CC, Fritz AG, Greene FL, Trotti A (Editors). AJCC Cancer Staging Manual. 7th Edition. New York: Springer, 2009.
15. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. BMJ 1997;315(7121):1533-7.
16. Enomoto H, Watanabe H, Nishikura K, Umezawa H, Asakura H. Topographic distribution of Helicobacter pylori in the resected stomach. European Journal of Gastroenterology and Hepatology 1998;10:473-8.
17. Eriksson NK, Kärkkäinen PA, Färkkilä MA, Arkkila PE. Prevalence and distribution of gastric intestinal metaplasia and its subtypes. Digestive and Liver Disease 2008;40(5):355-60.
18. Fennerty MB. Gastric intestinal metaplasia on routine endoscopic biopsy. Gastroenterology August 2003;125(2):586-90.
19. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, et al.Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-labelled, randomised control trial. Lancet 2008;372:350-2.
20. González CA, Pardo ML, Liso JM, Alonso P, Bonet C, Garcia RM, et al.Gastric cancer occurrence in preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. International Journal of Cancer 2010;127(11):2654-60.
21. González CA, Figueiredo C, Lic CB, Ferreira RM, Pardo ML, Ruiz Liso JM, et al.Helicobacter pylori cagA and vacA genotypes as predictors of progression of gastric preneoplastic lesions: a long-term follow-up in a high-risk area in Spain. American Journal of Gastroenterology 2011;106(5):867-74.
22. Hassan C, Zullo A, Di Giulio E, Annibale B, Lahner E, De Francesco V, et al.Cost-effectiveness of endoscopic surveillance for gastric intestinal metaplasia. Helicobacter 2010;15(3):221-6.
23. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org. Chichester: John Wiley & Sons.
24. Hirota WK, Zuckerman MJ, Adler DG, Davila RE, Egan J, Leighton JA, et al.ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointestinal Endoscopy 2006;23(4):570-80.
25. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al.Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012;61(5):646-64.
26. Moayyedi P, Hunt R, Forman D. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005583]
27. Murakami T. Pathomorphological diagnosis: definition and gross classification of early gastric cancer. In: Murakami T editor(s). Gann Monography on Cancer Research. Vol. 11, Tokyo: University of Tokyo Press, 1971:53-66.
28. Oda I, Suzuki H, Nonaka S, Yoshinaga S. Complications of gastric endoscopic submucosal dissection. Digestive Endoscopy 2013;25 Suppl 1:71-8.
29. Peleteiro B, Bastos J, Barros H, Lunet N. Systematic review of the prevalence of gastric intestinal metaplasia and its area-level association with smoking. Gaceta Sanitaria 2008;22(3):236-7.
30. Quine MA, Bell GD, McCloy RF, Matthews HR. Prospective audit of perforation rates following upper gastrointestinal endoscopy in two regions of England. British Journal of Surgery 1995;82(4):530-3.
31. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
32. Satoh K, Kimura K, Taniguchi Y, Kihira K, Takimoto T, Saifuku K, et al.Biopsy sites suitable for the diagnosis of Helicobacter pylori infection and the assessment of the extent of atrophic gastritis. American Journal of Gastroenterology 1998;93:569-73.
33. Shin WG, Kim HU, Song HJ, Hong SJ, Shim KN, Sung IK, et al.The Korean College of Helicobacter and Upper Gastrointestinal Research. Surveillance strategy of atrophic gastritis and intestinal metaplasia in a country with a high prevalence of gastric cancer. Digestive Diseases and Sciences 2012;57(3):746-52.
34. Tepes B. Can gastric cancer be prevented?. Journal of Physiology and Pharmacology 2009;60 Suppl 7:71-7.
35. Tsukuma H, Oshima A, Narahara H, Morii T. Natural history of early gastric cancer: a non-concurrent, long term, follow up study. Gut 2000;47(5):618-21.
36. Ubukata H, Katano M, Tabuchi T. A case of untreated gastric cancer followed for 7 years. Gastrointestinal Endoscopy 2004;60(3):476-80.
37. Uedo N, Iishi H, Tatsuta M, Ishihara R, Higashino K, Takeuchi Y, et al.Longterm outcomes after endoscopic mucosal resection for early gastric cancer. Gastric Cancer 2006;9(2):88-92.
38. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al.Helicobacter pylori infection and the development of gastric cancer. New England Journal of Medicine 2001;345(11):784-9.
39. Vilkin A, Half B, Moshkowitz M, Kariv R, Levi Z. Surveillance of patients with gastric intestinal metaplasia and dysplasia. Harefuah 2011;150(3):266-8.
40. Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, et al.Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54(6):764-8.
41. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, et al.Overweight, obesity and gastric cancer risk: results from a meta-analysis of cohort studies. European Journal of Cancer 2009;45(16):2867-73.
42. Yeh JM, Kuntz KM, Ezzati M, Goldie SJ. Exploring the cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer in China in anticipation of clinical trial results. International Journal of Cancer 2009;124(1):157-66.
43. Zhou L, Sung JJ, Lin S, Jin Z, Ding S, Huang X, et al.A five-year follow-up study on the pathological changes of gastric mucosa after H. pylori eradication. Chinese Medical Journal 2003;116(1):11-4.